ReviewHeart failure reviews2019
Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical impact, and management.
Review in Heart failure reviews, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 4 syntheses or guidelines pooled it, 68 citations in OpenAlex.
- Mavacamten and atrial fibrillation: assessing the risk through FAERS and meta-analysis.BMC cardiovascular disorders · 2026Pooled it
- Guidelines on the Diagnosis and Treatment of Hypertrophic Cardiomyopathy - 2024.Arquivos brasileiros de cardiologia · 2024Guideline
- Prognostic effect of atrial fibrillation on survival in patients with hypertrophic cardiomyopathy: a meta-analysis.Journal of cardiothoracic surgery · 2023Pooled it
- Anteriolateral versus anterior-posterior electrodes in external cardioversion of atrial fibrillation: A systematic review and meta-analysis of clinical trials.Clinical cardiology · 2023Pooled it
- Evidence for a role of adverse sarcomere signaling in atrial fibrillation induction.Journal of molecular and cellular cardiology plus · 2026Review
- Hypertrophic Cardiomyopathy and the Risk of Bradyarrhythmia and Permanent Pacemaker Implantation: A Nationwide Cohort Study.Clinical cardiology · 2026Article
- Electrophysiological Substrate and Ablation Outcomes in Atrial Fibrillation With Hypertrophic Cardiomyopathy: A Propensity-Matched Multicenter Study.Journal of arrhythmia · 2026Article
- Myocardial transit time mapping by CMR: A novel potential parameter of microcirculatory dysfunction in hypertrophic cardiomyopathy with and without atrial fibrillation.European journal of radiology open · 2026Article
- 2026 Expert Consensus Recommendations on Hypertrophic Cardiomyopathy: A Report of the Task Force of the Taiwan Society of Cardiology.Acta Cardiologica Sinica · 2026Article
- A machine Learning-Based risk stratification using CMR volumetric and strain parameters in patients with hypertrophic cardiomyopathy.The international journal of cardiovascular imaging · 2026Article
- Development, Validation, and Subtype Analysis of a Predictive Model for Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy.Reviews in cardiovascular medicine · 2025Article
- Integrative Approaches in the Management of Hypertrophic Cardiomyopathy: A Comprehensive Review of Current Therapeutic Modalities.Biomedicines · 2025Review
- Associations between new-onset postoperative atrial fibrillation and changes in left ventricular mass index in patients undergoing transcatheter aortic valve replacement.BMC cardiovascular disorders · 2025Article
- Clinical and Echocardiographic Particularities of Hypertrophic Cardiomyopathy in a Brazilian Population and its Prognostic Impact.Arquivos brasileiros de cardiologia · 2025Article
- The role of left atrio-ventricular coupling index and left atrial ejection fraction in predicting onset of atrial fibrillation and adverse cardiac events in hypertrophic cardiomyopathy.Cardiovascular ultrasound · 2025Article
- Complementary classification of hypertrophic cardiomyopathy using unsupervised cluster analysis on left ventricular function.Scientific reports · 2025Article
- Recent Clinical Updates of Hypertrophic Cardiomyopathy and Future Therapeutic Strategies.Reviews in cardiovascular medicine · 2025Review
- Atrial Fibrillation in Patients Receiving Mavacamten for Obstructive Hypertrophic Cardiomyopathy: Real-World Incidence, Management, and Outcomes.JACC. Clinical electrophysiology · 2025Article
- Advances in the study of S100A9 in cardiovascular diseases.Cell proliferation · 2024Review
- The abnormalities of free fatty acid metabolism in patients with hypertrophic cardiomyopathy, a single-center retrospective observational study.BMC cardiovascular disorders · 2024Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertrophic cardiomyopathy (HCM) is the most common hereditary cardiomyopathy characterized by left ventricular hypertrophy and spectrum of clinical manifestation. Atrial fibrillation (AF) is a common sustained arrhythmia in HCM patients and is primarily related to left atrial dilatation and remodeling. There are several clinical, electrocardiographic (ECG), and echocardiographic (ECHO) features that have been associated with development of AF in HCM patients; strongest predictors are left atrial size, age, and heart failure class. AF can lead to progressive functional decline, worsening heart failure and increased risk for systemic thromboembolism. The management of AF in HCM patient focuses on symptom alleviation (managed with rate and/or rhythm control methods) and prevention of complications such as thromboembolism (prevented with anticoagulation). Finally, recent evidence suggests that early rhythm control strategy may result in more favorable short- and long-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.